319460-85-0 Axitinib

Min.Order / FOB Price:Get Latest Price

1 Kilogram	FOB Price: USD 1000.0000

1 Kilogram

FOB Price: USD 1000.0000

Min.Order :1 Kilogram
Purity: 99%
Payment Terms : L/C,T/T

Keywords

319460-85-0 Axitinib C22H18N4OS

Quick Details

Appearance:white powder
Application:pharma
PackAge:as clients needs
ProductionCapacity:1|Metric Ton|Day
Storage:RT
Transportation:sea

Superiority:

Our company was built in 2009 with an ISO certificate.In the past 6 years, we have grown up as a famous fine chemicals supplier in China and we had established stable business relationships with Samsung,LG,Merck,Thermo Fisher Scientific and so on.Our main business covers the fields below:

1.Noble Metal Catalysts (Pt.Pd...)

2.Organic Phosphine Ligands (Tert-butyl-phosphine.Cyclohexyl-phosphine...)

3.OLED intermediates (Fluorene,Carbazole,Boric acid...)

4.Customs Synthesis

Our advantage:

1. Higest quality and good package

2.Fast delivery

3.Better payment term

4.Fast response to customer within 6 hours

5.Good business credit in Europe ,US ,Japan ,Korea

Anyway ,if you need any chemicals from China ,Henan Tianfu can help you

Details:

Axitinib Chemical Properties

Melting point 213-215°C

density 1.4

storage temp. -20°C Freezer

solubility DMSO: ≥8mg/mL

color white to tan

CAS DataBase Reference 319460-85-0(CAS DataBase Reference)

Safety Information

Hazard Codes Xn,N

Risk Statements 22-50/53

Safety Statements 60-61

RIDADR UN 3077 9 / PGIII

MSDS Information

Axitinib Usage And Synthesis

FDA approved axitinib use of treating advanced kidney cancer January 27, 2012, the FDA approved axitinib for the treatment of advanced kidney cancer (renal cell carcinoma) which other drugs unanswer . Inlyta is manufactured and sold by Pfizer,and is a oral pill taken twice a day.

Renal cell carcinoma is a type of tumor originating from the tubular endothelial cells. Axitinib can prevent certain protein called kinases playing a role in tumor growth and metastasis .

Axitinib is a small molecule tyrosine kinase inhibitor, effective against multiple targets, including VEGF receptors 1, 2 and 3.

Dr. Richard Pazdur, hematology and oncology drugs office director of FDA Drug Evaluation and Research Centre, said: "This is the seven kind of drugs allowed treating metastatic or advanced renal cell carcinoma since 2005 . Overall, during this time ,record level of drug development has dramatically changed the treatment of metastatic renal cell carcinoma paradigm, and offers a variety of treatment options for patients. "

In recent years, the drug has been approved for the treatment of kidney cancer include sorafenib (2005), sunitinib (2006), temsirolimus(2007), everolimus (2009), bevacizumab(2009) and pazopanib(2009).

The above information is edited by the chemicalbook of Tian Ye.

Chemical Properties Off-White Solid

View All

Visit Store